Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNITUDE Phase 3 study of NTLA-2001 in transthyretin amyloidosis with cardiomyopathy
2023-507220-23-00Phase 3Authorised
- Sponsor
- Intellia Therapeutics
- Start
- Jul 2024
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing NTLA-2001 with Placebo (2 arms). Primary endpoint: Composite outcome of cardiovascular mortality and cardiovascular events. Planned start Jul 2024; status: authorised.
02
Drugs
nexiguran ziclumeran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on 2023-507220-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507220-23-00.